ADPT

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Days

Hours

Mins

Sec

Claim Now

Peers: GRAL VCYT BLLN NTRA DGX LH QGEN A DHR TMO

| Held by: IWM VTI ARKG IWO VB IBB VXF FESM VBK SCHA

Scroll to Statements

Index	RUT
Market Cap	3.39B
Enterprise Value	3.39B
Income	-49.68M
Sales	295.41M
Book/sh	1.35
Cash/sh	1.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	624
IPO	Jun 27, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	11.48
P/B	15.64
P/C	15.53
P/FCF	-
EV/EBITDA	-
EV/Sales	11.47
Quick Ratio	3.22
Current Ratio	3.35
Debt/Eq	0.96
LT Debt/Eq	0.90
Option/Short	Yes / Yes

EPS (ttm)	-0.33
EPS next Y	-0.25
EPS next Q	-0.14
EPS this Y	-18.24%
EPS next Y	46.55%
EPS next 5Y	34.30%
EPS past 3/5Y	34.64% 18.85%
Sales past 3/5Y	14.34% 23.00%
EPS Y/Y TTM	66.29%
Sales Y/Y TTM	55.87%
EPS Q/Q	35.63%
Sales Q/Q	35.14%
Earnings	May 05 AMC
EPS/Sales Surpr.	19.00% 16.16%

Insider Own	3.45%
Insider Trans	-39.27%
Inst Own	95.08%
Inst Trans	0.79%
ROA	-9.77%
ROE	-24.43%
ROIC	-12.11%
Gross Margin	71.64%
Oper. Margin	-15.48%
Profit Margin	-16.82%
SMA20	13.62%
SMA50	33.29%
SMA200	34.19%
Trades

Shs Outstand	159.70M
Shs Float	154.52M
Short Float	4.95%
Short Ratio	3.11
Short Interest	7.65M
52W High	22.54 -5.99%
52W Low	9.96 112.86%
Volatility	5.44% 7.73%
ATR (14)	1.20
RSI (14)	67.44
Beta	2.08
Rel Volume	1.38
Avg Volume	2.46M
Volume	3,391,524

Perf Week	4.64%
Perf Month	39.96%
Perf Quarter	46.85%
Perf Half Y	29.05%
Perf YTD	30.48%
Perf Year	84.58%
Perf 3Y	215.80%
Perf 5Y	-46.10%
Perf 10Y	-
Recom	1.25
Target Price	20.29
Prev Close	22.37
Price	21.19
Change	-5.27%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight	$21
Sep-30-25	Initiated	Guggenheim	Buy	$20
Jun-18-25	Initiated	Craig Hallum	Buy	$15
Mar-21-25	Upgrade	Goldman	Neutral → Buy	$9
Jul-05-23	Resumed	JP Morgan	Overweight	$15
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$15
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight	$7.50 → $14
Aug-25-22	Initiated	Credit Suisse	Underperform	$8
Jun-03-22	Initiated	Piper Sandler	Neutral	$7.50
Feb-16-22	Reiterated	JP Morgan	Overweight	$75 → $50
Feb-16-22	Reiterated	Goldman	Neutral	$54 → $21
Feb-16-22	Reiterated	BTIG Research	Buy	$35 → $30
Feb-16-22	Reiterated	BofA Securities	Buy	$40 → $32
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral	$74 → $63
Oct-08-20	Resumed	BTIG Research	Buy	$60
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight	$42
Jun-03-20	Initiated	Goldman	Buy	$60
Jul-23-19	Initiated	BTIG Research	Buy	$46
Jul-22-19	Initiated	William Blair	Outperform

Show Previous Ratings

Jun-30-26 04:10PM	Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial (Exec Edge)
Jun-17-26 06:00AM	Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering (GlobeNewswire)
Jun-15-26 04:10PM	Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses (GlobeNewswire)
04:05PM	Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering (GlobeNewswire)
May-29-26 07:30AM	At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ MRD Testing Across Hematology Clinical Practice and Research (GlobeNewswire)
04:17PM	Loading…
May-21-26 04:17PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-05-26 05:01PM	Adaptive Biotechnologies: Q1 Earnings Snapshot (Associated Press)
04:05PM	Adaptive Biotechnologies Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-15-26 04:05PM	Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 (GlobeNewswire)
Mar-02-26 08:10PM	Adaptive Biotechnologies CEO Flags MRD Momentum, Lifts 2025 Volume Outlook to 30%+ at TD Cowen Conf. (MarketBeat)
Feb-28-26 02:14AM	Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)? (Insider Monkey)
Feb-21-26 06:01AM	TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT) (Insider Monkey)
Feb-06-26 08:30AM	Adaptive Biotechnologies Corporation Q4 2025 Earnings Call Summary (Moby)
12:05AM	Adaptive Biotechnologies Corp (ADPT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-05-26 08:06PM	Adaptive Biotechnologies Q4 Earnings Call Highlights (MarketBeat)
07:30PM	Loading…
07:30PM	Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:53PM	Adaptive Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Jan-27-26 04:05PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-22-26 04:05PM	Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 (GlobeNewswire) +8.48%
Jan-13-26 09:40AM	What's Going On With Adaptive Biotechnologies Shares Tuesday? (Benzinga)
Jan-12-26 09:06PM	Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026 (MarketBeat) +15.86%
07:30AM	Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results (GlobeNewswire)
Dec-30-25 04:05PM	Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 08:00AM	Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer (GlobeNewswire)
Dec-09-25 05:07PM	Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease (GlobeNewswire) +5.92%
Dec-08-25 02:16AM	Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake (Insider Monkey)
Dec-06-25 08:30AM	Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting (GlobeNewswire)
Nov-24-25 07:30AM	Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting (GlobeNewswire) +9.94%
10:10AM	Loading…
Nov-22-25 10:10AM	Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why (Insider Monkey)
Nov-17-25 09:05AM	Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3 (Insider Monkey)
Nov-06-25 04:05PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire) -11.54%
07:05AM	Cathie Wood Loads Up Pinterest After Sell-Off -- Dumps Shopify, Roku, and Robinhood (GuruFocus.com)
12:03AM	Adaptive Biotechnologies Corp (ADPT) Q3 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Nov-05-25 07:30PM	Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
06:35PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:31PM	Adaptive Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 07:45AM	Adaptive Biotechnologies Corp (ADPT) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 10:00AM	Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-23-25 10:19AM	IQVIA Gears Up to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-17-25 12:10PM	Can This Red-Hot Biotech Stock Live Up to Wall Streets Expectations? (Barchart) -5.62%
Oct-15-25 04:05PM	Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire) +9.82%
Sep-26-25 10:32AM	LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy (Zacks)
09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
Sep-23-25 12:08PM	CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU (Zacks)
Sep-19-25 12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-11-25 11:57AM	FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer (Zacks) +8.62%
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
09:40AM	Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks)
10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Sep-04-25 10:48AM	SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study (Zacks)
Sep-01-25 12:30PM	Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice (Zacks)
Aug-29-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-27-25 04:05PM	Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-25-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
12:08AM	Adaptive Biotechnologies (ADPT) Poised for $33.7M Windfall on Genentech Deal Termination (Insider Monkey)
Aug-19-25 07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive)
Aug-13-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Aug-08-25 09:40AM	Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-06-25 07:01PM	Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday (Motley Fool) +5.79% +7.27%
03:30AM	Adaptive Biotechnologies Corp (ADPT) Q2 2025 Earnings Call Highlights: Strong MRD Growth and ... (GuruFocus.com)
Aug-05-25 07:30PM	Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings (Zacks)
06:00PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:57PM	Adaptive Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:38AM	Adaptive Biotechnologies Corp (ADPT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.61%
Aug-01-25 08:10AM	Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-22-25 08:14AM	Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results (Insider Monkey)
Jul-15-25 04:05PM	Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 (GlobeNewswire)
Jul-04-25 09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
Jul-01-25 07:30AM	Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ MRD Testing into OncoEMR (GlobeNewswire)
Jun-26-25 09:49AM	Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains? (Zacks)
Jun-25-25 01:01PM	Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy (Insider Monkey) +12.49%
Jun-13-25 12:00PM	What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock (Zacks)
Jun-11-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-03-25 04:05PM	Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors (Business Wire)
May-30-25 07:30AM	Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers (GlobeNewswire)
May-29-25 11:18AM	SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal (Zacks)
11:08AM	U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot (Zacks)
06:20AM	Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? (Zacks)
May-28-25 04:05PM	Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-26-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
May-20-25 06:20AM	Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar? (Zacks)
May-19-25 09:06AM	BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz (Zacks)
May-15-25 08:42AM	AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer (Zacks)
May-14-25 06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
May-09-25 12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
12:00PM	Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy? (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
May-08-25 09:55AM	Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect? (Zacks) +5.22%
09:40AM	Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? (Zacks)
May-02-25 09:29AM	Q1 2025 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents) +33.70%
03:18AM	Adaptive Biotechnologies Corp (ADPT) Q1 2025 Earnings Call Highlights: Strong MRD Revenue ... (GuruFocus.com)

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Co-FounderMr. Chad M. Robins M.B.A.

President & COOMs. Julie Rubinstein

Co-Founder & Chief Scientific OfficerDr. Harlan S. Robins Ph.D.

VPMr. Kyle Piskel

Chief Commercial Officer of MRDMs. Susan Bobulsky

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FRANCIS LO	Officer	Jul 01 '26	Proposed Sale	21.45	199,260	4,274,127		Jul 01 04:35 PM
SUSAN BOBULSKY	Officer	Jul 01 '26	Proposed Sale	21.45	487	10,446		Jul 01 04:16 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Jun 29 '26	Option Exercise	7.28	103,295	751,602	376,046	Jun 30 07:25 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Jun 26 '26	Option Exercise	12.14	11,034	133,953	283,785	Jun 30 07:25 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Jun 29 '26	Sale	21.14	154,768	3,271,796	221,278	Jun 30 07:25 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Jun 26 '26	Sale	21.00	11,034	231,714	272,751	Jun 30 07:25 PM
SHARON BENZENO	Officer	Jun 29 '26	Proposed Sale	20.96	152,931	3,205,434		Jun 29 04:48 PM
SHARON BENZENO	Officer	Jun 26 '26	Proposed Sale	20.25	12,871	260,638		Jun 26 04:42 PM
SUSAN BOBULSKY	Officer	Jun 25 '26	Proposed Sale	19.34	5,000	96,700		Jun 25 04:26 PM
MICHELLE GRIFFIN	Director	Jun 25 '26	Proposed Sale	19.34	52,084	1,007,305		Jun 25 04:26 PM
ROBINS HARLAN S	Chief Scientific Officer	Jun 15 '26	Sale	17.37	100,000	1,737,000	1,412,058	Jun 17 08:11 PM
ROBINS HARLAN S	Chief Scientific Officer	Jun 16 '26	Sale	18.01	6,160	110,942	1,405,898	Jun 17 08:11 PM
Harlan Robins	Officer	Jun 16 '26	Proposed Sale	17.22	6,160	106,075		Jun 16 06:04 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Jun 11 '26	Sale	19.00	5,000	95,000	411,775	Jun 15 07:13 PM
Harlan Robins	Officer	Jun 15 '26	Proposed Sale	17.46	100,000	1,746,000		Jun 15 06:10 PM
SUSAN BOBULSKY	Officer	Jun 11 '26	Proposed Sale	17.07	5,000	85,350		Jun 11 04:37 PM
LO FRANCIS	Chief People Officer	Jun 04 '26	Option Exercise	8.85	19,521	172,797	290,675	Jun 08 08:29 PM
LO FRANCIS	Chief People Officer	Jun 04 '26	Sale	17.49	39,741	695,070	250,934	Jun 08 08:29 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Jun 04 '26	Sale	18.00	11,000	198,000	416,775	Jun 08 08:27 PM
SUSAN BOBULSKY	Officer	Jun 04 '26	Proposed Sale	15.99	11,000	175,890		Jun 04 04:34 PM
FRANCIS LO	Officer	Jun 04 '26	Proposed Sale	15.99	42,085	672,939		Jun 04 04:27 PM
PISKEL KYLE	Chief Financial Officer	May 18 '26	Sale	13.04	3,115	40,620	256,725	May 20 07:13 PM
PISKEL KYLE	Officer	May 18 '26	Proposed Sale	12.83	3,160	40,543		May 15 08:03 PM
RUBINSTEIN JULIE	President and COO	Apr 27 '26	Option Exercise	8.46	14,707	124,421	396,839	Apr 29 07:08 PM
RUBINSTEIN JULIE	President and COO	Apr 27 '26	Sale	14.23	19,037	270,897	377,802	Apr 29 07:08 PM
RUBINSTEIN JULIE	President and COO	Apr 22 '26	Option Exercise	8.46	14,722	124,548	409,868	Apr 24 06:29 PM
RUBINSTEIN JULIE	President and COO	Apr 23 '26	Option Exercise	8.46	14,722	124,548	405,530	Apr 24 06:29 PM
RUBINSTEIN JULIE	President and COO	Apr 24 '26	Option Exercise	8.46	14,722	124,548	401,192	Apr 24 06:29 PM
RUBINSTEIN JULIE	President and COO	Apr 22 '26	Sale	14.13	19,060	269,318	390,808	Apr 24 06:29 PM
RUBINSTEIN JULIE	President and COO	Apr 24 '26	Sale	14.02	19,060	267,221	382,132	Apr 24 06:29 PM
RUBINSTEIN JULIE	President and COO	Apr 23 '26	Sale	13.74	19,060	261,884	386,470	Apr 24 06:29 PM
RUBINSTEIN JULIE	President and COO	Apr 21 '26	Option Exercise	10.10	26,603	268,783	426,087	Apr 21 06:07 PM
RUBINSTEIN JULIE	President and COO	Apr 17 '26	Option Exercise	8.46	14,722	124,548	422,882	Apr 21 06:07 PM
RUBINSTEIN JULIE	President and COO	Apr 20 '26	Option Exercise	8.46	14,722	124,548	418,544	Apr 21 06:07 PM
RUBINSTEIN JULIE	President and COO	Apr 21 '26	Sale	14.66	30,941	453,595	395,146	Apr 21 06:07 PM
RUBINSTEIN JULIE	President and COO	Apr 17 '26	Sale	14.57	19,060	277,704	403,822	Apr 21 06:07 PM
RUBINSTEIN JULIE	President and COO	Apr 20 '26	Sale	14.55	19,060	277,323	399,484	Apr 21 06:07 PM
RUBINSTEIN JULIE	President and COO	Apr 14 '26	Option Exercise	8.46	14,722	124,548	435,896	Apr 16 07:36 PM
RUBINSTEIN JULIE	President and COO	Apr 15 '26	Option Exercise	8.46	14,722	124,548	431,558	Apr 16 07:36 PM
RUBINSTEIN JULIE	President and COO	Apr 16 '26	Option Exercise	8.46	14,722	124,548	427,220	Apr 16 07:36 PM
RUBINSTEIN JULIE	President and COO	Apr 15 '26	Sale	14.61	19,060	278,467	412,498	Apr 16 07:36 PM
RUBINSTEIN JULIE	President and COO	Apr 14 '26	Sale	14.56	19,060	277,514	416,836	Apr 16 07:36 PM
RUBINSTEIN JULIE	President and COO	Apr 16 '26	Sale	14.18	19,060	270,271	408,160	Apr 16 07:36 PM
RUBINSTEIN JULIE	President and COO	Apr 13 '26	Option Exercise	7.80	14,722	114,898	440,234	Apr 13 07:44 PM
RUBINSTEIN JULIE	President and COO	Apr 09 '26	Option Exercise	7.27	14,722	107,029	448,910	Apr 13 07:44 PM
RUBINSTEIN JULIE	President and COO	Apr 10 '26	Option Exercise	7.27	14,722	107,029	444,572	Apr 13 07:44 PM
RUBINSTEIN JULIE	President and COO	Apr 09 '26	Sale	13.86	19,060	264,202	429,850	Apr 13 07:44 PM
RUBINSTEIN JULIE	President and COO	Apr 13 '26	Sale	13.15	19,060	250,599	421,174	Apr 13 07:44 PM
RUBINSTEIN JULIE	President and COO	Apr 10 '26	Sale	12.77	19,060	243,307	425,512	Apr 13 07:44 PM
LO FRANCIS	Chief People Officer	Apr 08 '26	Option Exercise	3.99	2,344	9,353	293,718	Apr 10 06:52 PM
LO FRANCIS	Chief People Officer	Apr 08 '26	Sale	15.07	22,564	340,039	271,154	Apr 10 06:52 PM
ROBINS HARLAN S	Chief Scientific Officer	Apr 08 '26	Sale	14.85	10,000	148,500	1,512,058	Apr 10 06:48 PM
ROBINS CHAD M	CEO and Chairman	Apr 06 '26	Sale	14.41	83,332	1,200,814	2,217,781	Apr 08 07:51 PM
ROBINS CHAD M	CEO and Chairman	Apr 08 '26	Sale	15.19	37,263	566,025	2,180,518	Apr 08 07:51 PM
RUBINSTEIN JULIE	President and COO	Apr 08 '26	Option Exercise	9.44	26,603	251,264	465,129	Apr 08 07:48 PM
RUBINSTEIN JULIE	President and COO	Apr 06 '26	Option Exercise	7.27	14,722	107,029	461,924	Apr 08 07:48 PM
RUBINSTEIN JULIE	President and COO	Apr 07 '26	Option Exercise	7.27	14,722	107,029	457,586	Apr 08 07:48 PM
RUBINSTEIN JULIE	President and COO	Apr 08 '26	Sale	14.83	30,941	458,920	434,188	Apr 08 07:48 PM
RUBINSTEIN JULIE	President and COO	Apr 06 '26	Sale	14.33	19,060	273,130	442,864	Apr 08 07:48 PM
RUBINSTEIN JULIE	President and COO	Apr 07 '26	Sale	13.56	19,060	258,454	438,526	Apr 08 07:48 PM
Harlan Robins	Officer	Apr 08 '26	Proposed Sale	14.84	10,000	148,400		Apr 08 04:58 PM
Chad Robins	Officer	Apr 08 '26	Proposed Sale	14.84	37,263	552,983		Apr 08 04:58 PM
FRANCIS LO	Officer	Apr 08 '26	Proposed Sale	13.71	22,564	309,352		Apr 08 04:33 PM
Chad Robins	Officer	Apr 06 '26	Proposed Sale	14.08	83,332	1,173,315		Apr 06 05:22 PM
RUBINSTEIN JULIE	President and COO	Apr 01 '26	Option Exercise	7.27	14,722	107,029	470,600	Apr 02 07:16 PM
RUBINSTEIN JULIE	President and COO	Apr 02 '26	Option Exercise	7.27	14,722	107,029	466,262	Apr 02 07:16 PM
RUBINSTEIN JULIE	President and COO	Apr 02 '26	Sale	14.60	19,060	278,276	447,202	Apr 02 07:16 PM
RUBINSTEIN JULIE	President and COO	Apr 01 '26	Sale	14.45	19,060	275,417	451,540	Apr 02 07:16 PM
RUBINSTEIN JULIE	President and COO	Mar 27 '26	Option Exercise	7.27	14,722	107,029	483,614	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 30 '26	Option Exercise	7.27	14,722	107,029	479,276	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 31 '26	Option Exercise	7.27	14,722	107,029	474,938	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 31 '26	Sale	13.45	19,060	256,357	455,878	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 27 '26	Sale	13.34	19,060	254,218	464,554	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 30 '26	Sale	12.63	19,060	240,728	460,216	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 24 '26	Option Exercise	7.27	14,722	107,029	496,628	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 25 '26	Option Exercise	7.27	14,722	107,029	492,290	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 26 '26	Option Exercise	7.27	14,722	107,029	487,952	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 25 '26	Sale	14.27	19,060	271,986	473,230	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 26 '26	Sale	14.12	19,060	269,127	468,892	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 24 '26	Sale	13.70	19,060	261,122	477,568	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 23 '26	Option Exercise	7.27	14,722	107,029	500,966	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 20 '26	Option Exercise	7.08	14,722	104,193	505,304	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 19 '26	Option Exercise	6.55	14,722	96,429	509,642	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 23 '26	Sale	13.83	19,060	263,600	481,906	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 20 '26	Sale	13.37	19,060	254,832	486,244	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 19 '26	Sale	13.18	19,060	251,211	490,582	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 16 '26	Option Exercise	6.55	14,722	96,429	522,656	Mar 18 06:21 PM
RUBINSTEIN JULIE	President and COO	Mar 17 '26	Option Exercise	6.55	14,722	96,429	518,318	Mar 18 06:21 PM
RUBINSTEIN JULIE	President and COO	Mar 18 '26	Option Exercise	6.55	14,722	96,429	513,980	Mar 18 06:21 PM
RUBINSTEIN JULIE	President and COO	Mar 16 '26	Sale	13.41	19,060	255,595	503,596	Mar 18 06:21 PM
RUBINSTEIN JULIE	President and COO	Mar 17 '26	Sale	13.40	19,060	255,404	499,258	Mar 18 06:21 PM
RUBINSTEIN JULIE	President and COO	Mar 18 '26	Sale	13.18	19,060	251,211	494,920	Mar 18 06:21 PM
BOBULSKY SUSAN	Officer	Mar 11 '26	Proposed Sale	14.52	41,338	600,228		Mar 16 09:05 PM
BENZENO SHARON	Officer	Mar 11 '26	Proposed Sale	14.52	63,103	916,256		Mar 16 09:00 PM
PISKEL KYLE	Officer	Mar 11 '26	Proposed Sale	14.52	18,672	271,117		Mar 16 08:53 PM
RUBINSTEIN JULIE	Officer	Mar 11 '26	Proposed Sale	14.52	122,523	1,779,034		Mar 16 08:46 PM
ROBINS HARLAN S	Officer	Mar 11 '26	Proposed Sale	14.52	470,266	6,828,262		Mar 16 08:40 PM
ROBINS CHAD M	Officer	Mar 11 '26	Proposed Sale	14.52	470,167	6,826,825		Mar 16 08:33 PM
RUBINSTEIN JULIE	President and COO	Mar 11 '26	Option Exercise	6.55	14,722	96,429	535,670	Mar 13 09:36 PM
RUBINSTEIN JULIE	President and COO	Mar 13 '26	Option Exercise	6.55	14,722	96,429	526,994	Mar 13 09:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

Adaptive Biotechnologies Corp

Upgrade your Finviz experience